TGFB1 and neoplasm: PLGA‐POx‐RGD (30% m/m) NP were therefore selected to deliver combinations of immune potentiators (CpG‐ODN and Poly(I:C)) and siTGF‐β1 to modulate tumor‐infiltrating immune cell sub‐populations and silence the expression of the potent immune suppressor TGF‐β1 cytokine within tumor milieu.